In his role, Ray is expected to lead business development efforts aimed at expanding the company’s pipeline of differentiated protein therapeutics.
Prior to joining Itero, Ray was the associate director of Business Development at Portola Pharmaceuticals.
Itero senior vice president and chief commercial officer Jerald Beers said that Debanjan was instrumental in closing the recently announced global licensing deal with Watson Pharmaceuticals for our first program.
“He is currently spearheading our business development efforts to expand Itero’s pipeline via in-licensing, collaborations, or the acquisition of protein drug candidates to which we can apply our extensive biologics development and commercialisation knowledge and experience, Beers said.